Eduovisual
Pediatrics (System-Integrated)
Pediatric obesity: assessment and counseling
— Overweight: BMI ≥85th to <95th percentile for age/sex
— Obesity (Class I): BMI ≥95th percentile
— Class II obesity: BMI ≥120% of 95th percentile or ≥35 kg/m²
— Class III (severe): BMI ≥140% of 95th percentile or ≥40 kg/m²
— Under age 2: use WHO weight-for-length ≥97.7th percentile (not BMI)
— ~20% of US children/adolescents have obesity; higher prevalence in Hispanic, non-Hispanic Black, and low-income populations
— Tracks into adulthood: ~80% of adolescents with obesity become adults with obesity
— Drives early type 2 diabetes, NAFLD, OSA, dyslipidemia, hypertension, depression, and orthopedic complications (SCFE, Blount disease)
— AAP 2023 guideline: calculate and plot BMI at every well-child visit starting age 2
— Flag any upward percentile crossing even within normal range
— Screen earlier if family history of severe obesity, T2DM, or premature CVD
— Short stature + obesity → endocrine (hypothyroidism, Cushing, GH deficiency)
— Obesity before age 5 + hyperphagia → monogenic (MC4R, leptin/leptin-R, POMC)
— Developmental delay/dysmorphism → syndromic (Prader-Willi, Bardet-Biedl, fragile X)
— Rapid weight gain after CNS insult → hypothalamic obesity
Board pearl: A child with obesity who is tall and tracking on their growth curve has exogenous obesity. A child with obesity who is short or has decelerating linear growth needs an endocrine workup — this is the single highest-yield Step 3 discriminator.
Step 3 management: AAP now recommends immediate, intensive treatment at diagnosis — the era of "watchful waiting" is over. Even mild overweight warrants structured counseling, not reassurance.
— Parents present for snoring/daytime sleepiness (OSA), knee or hip pain (Blount, SCFE), acanthosis nigricans ("dirty neck"), menstrual irregularity/hirsutism (PCOS), school refusal/bullying, or abnormal screening labs
— Many cases are identified only because the clinician plotted BMI
— Dietary patterns: sugar-sweetened beverages (juice, soda, sports drinks), fast food frequency, portion sizes, eating while screen-watching, skipped breakfast, fruit/vegetable servings
— Activity: ≥60 minutes/day moderate-vigorous physical activity (current AAP/HHS target)
— Screen time: ≥2 hours/day recreational is excessive; none under 18 months except video chat
— Sleep: short sleep duration is independently obesogenic — age-specific targets (preschool 10–13h, school-age 9–12h, teens 8–10h)
— Beverages: zero sugar-sweetened beverages is the target
— Food insecurity (paradoxically associated with obesity), neighborhood walkability, access to safe play, school lunch quality
— Adverse childhood experiences (ACEs), depression, anxiety, history of trauma/abuse
— Family meals frequency, parenting style around food (restrictive vs permissive)
Key distinction: Exogenous obesity history features gradual weight gain over years, normal development, family obesogenic environment. Hyperphagic, insatiable hunger from infancy suggests monogenic obesity (MC4R most common) and warrants genetics referral.
Board pearl: Always ask about bullying and mood — depression prevalence is 2–3× higher and influences both etiology and treatment adherence.
— Height without shoes on stadiometer, weight in light clothing, calculate BMI and plot percentile — record absolute BMI and % of 95th percentile (for severe obesity classification)
— Waist circumference is not routinely required in pediatrics
— Blood pressure with appropriately sized cuff (bladder width ≥40% of arm circumference; too-small cuff falsely elevates BP) — repeat ×3 if elevated
— Pediatric HTN: BP ≥95th percentile for age/sex/height on 3 occasions (or ≥130/80 in adolescents ≥13)
— Resting tachycardia may suggest deconditioning or hyperthyroidism mimic
— Acanthosis nigricans (posterior neck, axillae) — marker of insulin resistance, not a skin disease
— Tonsillar hypertrophy, crowded oropharynx (Mallampati III–IV) → OSA risk
— Moon facies, buffalo hump, supraclavicular fat pad → Cushing
— Goiter → thyroid disease
— Gynecomastia (true vs lipomastia) in boys
— Striae: pink/pale striae are common with rapid growth; wide purple striae suggest Cushing
— Hepatomegaly → NAFLD/NASH
— Document Tanner stage; premature adrenarche and early menarche are common
— Buried penis in boys (often parental concern, usually anatomic from suprapubic fat)
— Hirsutism, acne in girls → PCOS
— Genu varum after age 4 → Blount disease
— Limp, hip/knee pain, externally rotated leg → SCFE (urgent imaging, non-weight-bearing)
— Pseudotumor cerebri: papilledema, headaches, CN VI palsy
— Flat affect, slow speech → screen depression/hypothyroid
Step 3 management: Any obese adolescent with hip or referred knee pain gets bilateral hip frog-leg radiographs immediately and is made non-weight-bearing — missing SCFE causes avascular necrosis.
Board pearl: Acanthosis nigricans is the single most reliable physical sign predicting insulin resistance and warrants metabolic screening.
— Fasting lipid panel
— ALT and AST (NAFLD screen)
— Fasting glucose or HbA1c (and consider fasting insulin if needed)
— Fasting lipid panel
— ALT/AST
— Fasting glucose and HbA1c (some add 2-hour OGTT if A1c borderline)
— NAFLD screen: ALT >22 U/L girls / >26 U/L boys is abnormal in pediatrics (NOT the adult lab cutoff); persistent elevation >3 months → hepatology/GI referral, ultrasound, evaluate for other causes (Wilson, autoimmune hepatitis, viral)
— Dyslipidemia: non-HDL ≥145, LDL ≥130, TG ≥130 (10–19 yr), HDL <40 mg/dL
— Prediabetes: HbA1c 5.7–6.4%, fasting glucose 100–125; T2DM: A1c ≥6.5% or fasting ≥126
— TSH only if linear growth deceleration, fatigue, or cold intolerance — routine TSH not recommended in eutrophic obese kids
— Cushing workup (24-hr UFC, late-night salivary cortisol, low-dose dex) only if classic features
— Vitamin D if at risk
— PCOS workup in adolescent girls with oligomenorrhea ≥2 years post-menarche + hyperandrogenism
— Polysomnography if snoring, witnessed apnea, daytime sleepiness, or enuresis returning — gold standard; pulse ox screening insufficient
— RUQ ultrasound if persistent ALT elevation
Key distinction: Use pediatric ALT cutoffs (22/26), not adult lab "normal" ranges — labs frequently report adult ranges and miss NAFLD. This is a classic Step 3 trap.
Board pearl: Routine TSH screening in obese children is low-yield and not recommended; reserve for clinical suspicion (short stature, growth failure).
— Exclude: viral hepatitis (HBsAg, anti-HCV), Wilson disease (ceruloplasmin, 24-hr urine copper if <40 yr), autoimmune hepatitis (ANA, ASMA, anti-LKM, IgG), alpha-1 antitrypsin, celiac, hemochromatosis, drug-induced
— MR elastography or FibroScan to assess fibrosis without biopsy
— Liver biopsy if diagnostic uncertainty or to grade NASH/fibrosis — referral to pediatric hepatology
— GAD-65, IA-2, insulin, ZnT8 antibodies to exclude T1DM (overlap is common — "double diabetes")
— C-peptide if ambiguous
— Baseline microalbuminuria, dilated eye exam, foot exam, lipid panel
— Repeat A1c every 3 months
— AHI ≥1 in children is abnormal; ≥5 is moderate, ≥10 severe
— ENT referral for adenotonsillectomy (first-line in children)
— Persistent OSA post-T&A → CPAP, weight loss, possible craniofacial workup
— Microarray for syndromic features
— Methylation studies for Prader-Willi (suspect with hypotonia infancy, hyperphagia age 2–6, hypogonadism)
— Targeted gene panel (MC4R, LEP, LEPR, POMC, PCSK1) if early-onset severe obesity (<5 yr) + hyperphagia
— Refer to genetics/endocrine
— ECG and echocardiogram if HTN confirmed, severe obesity considering pharmacotherapy/surgery, or symptoms
— Ambulatory BP monitoring (ABPM) confirms HTN diagnosis and distinguishes white-coat HTN
Step 3 management: A 14-year-old with BMI 38, A1c 6.8%, and positive GAD antibodies has autoimmune diabetes with obesity comorbidity, not pure T2DM — insulin is required, and management differs significantly.
Board pearl: Genetic obesity panels are now indicated and actionable — setmelanotide is FDA-approved for POMC, LEPR, PCSK1, and Bardet-Biedl deficiency.
— No "watchful waiting" — obesity is a chronic disease, treat at diagnosis
— Use the most intensive treatment appropriate for age and severity, available within the family's resources
— Intensive Health Behavior and Lifestyle Treatment (IHBLT)
— Defined as ≥26 contact hours over 3–12 months, face-to-face, family-based, multicomponent (nutrition, physical activity, behavior change)
— More hours = better outcomes; 52+ hours optimal
— Engages whole family, not just the child
— Age 2–5: IHBLT only
— Age 6–11: IHBLT; consider pharmacotherapy in select cases with severe comorbidities
— Age ≥12 with obesity (BMI ≥95th): IHBLT plus consider pharmacotherapy as adjunct
— Age ≥13 with severe obesity (BMI ≥120% of 95th or ≥35): evaluate for metabolic and bariatric surgery at comprehensive center
— Ask permission to discuss weight; use neutral, non-stigmatizing language ("higher weight," "BMI" rather than "fat" or "obese child")
— Explore readiness to change; set SMART goals (Specific, Measurable, Achievable, Relevant, Time-bound)
— Focus on behaviors, not numbers
— Younger children (<7) with no comorbidities: weight maintenance while growing in height
— Older children/comorbidities: gradual loss of 1–2 lb/week
— Avoid restrictive dieting in pre-pubertal children (growth concerns)
Key distinction: Lifestyle change is necessary but often insufficient for severe obesity. Step 3 expects you to recognize when to escalate, not endlessly cycle "diet and exercise."
Step 3 management: A motivated 14-year-old with BMI 36 and prediabetes has already failed 6 months of lifestyle counseling → add pharmacotherapy (e.g., semaglutide) rather than repeat the same approach.
— GI lipase inhibitor; modest 2–3% BMI reduction
— GI side effects (steatorrhea, oily spotting) limit adherence; rarely used
— GLP-1 receptor agonist, daily SC injection
— ~5% BMI reduction; titrate weekly to 3 mg/day
— Side effects: nausea, vomiting; pancreatitis (rare); contraindicated with personal/family history MTC or MEN2
— Weekly SC GLP-1 agonist; most effective pharmacotherapy currently
— ~16% BMI reduction at 68 weeks in adolescents (STEP TEENS)
— Same class warnings as liraglutide
— Cost and access major barriers — Step 3 may test on insurance/prior authorization
— Sympathomimetic; controlled substance
— Limited to 12 weeks; CV side effects; not first-line
— Combination; effective but topiramate teratogen → contraception required; cognitive side effects
— Monitor for nephrolithiasis, paresthesias, metabolic acidosis
— MC4R agonist for specific monogenic obesity (POMC, PCSK1, LEPR deficiency; Bardet-Biedl)
— Daily SC injection; remarkable response in eligible patients
— Requires genetic confirmation
— Modest weight effect (~1–2 kg); useful when prediabetes/PCOS coexists
— Not formally approved for obesity alone
— Pharmacotherapy is adjunct to IHBLT, never replacement
— Reassess at 3 months; discontinue if <4% BMI reduction
— Long-term continuation expected (chronic disease model)
Board pearl: Stopping GLP-1 agonists reliably causes weight regain — counsel families upfront that this is chronic therapy, like antihypertensives, not a "course" of treatment.
Step 3 management: Pair pharmacotherapy initiation with ongoing IHBLT visits and labs (A1c, lipids, ALT) every 3 months.
— BMI ≥35 or 120% of 95th percentile WITH a major comorbidity (T2DM, moderate-severe OSA, NASH with fibrosis, pseudotumor cerebri, severe HTN, GERD, hip/knee disease)
— BMI ≥40 or 140% of 95th percentile regardless of comorbidities
— Tanner stage ≥4 and near-final adult height typically preferred but not strict requirements
— Demonstrated engagement in lifestyle program (not necessarily success)
— Referral to multidisciplinary pediatric bariatric center (surgeon, dietitian, psychologist, endocrinologist, social work)
— Vertical sleeve gastrectomy (VSG): most common in adolescents; removes ~80% of stomach; lower complication rate, no malabsorption, no foreign material
— Roux-en-Y gastric bypass (RYGB): greater weight loss and superior T2DM remission, but higher complication rate, micronutrient deficiencies, dumping syndrome
— Adjustable gastric banding: not recommended in adolescents (high failure/removal rates)
— ~25–30% sustained total body weight loss at 5 years
— T2DM remission ~95%, HTN remission ~75%, dyslipidemia ~60%
— Some bone density loss; nutritional deficiencies common (B12, iron, vitamin D, thiamine)
— Lifelong multivitamin, calcium, vitamin D, B12
— Annual labs: CBC, iron studies, B12, folate, 25-OH D, PTH, A1c, lipids
— Pregnancy avoidance for ≥12–18 months post-op; contraception counseling essential (oral contraceptive absorption altered after RYGB → consider IUD/implant)
— Mental health surveillance — suicide risk increases post-bariatric surgery, especially adolescents
— Untreated eating disorder, active substance use, inability to comply with follow-up, unmanaged psychiatric illness
Board pearl: Bariatric surgery in adolescents is underutilized, not overutilized — eligible patients are routinely denied. Step 3 expects you to refer, not gatekeep.
CCS pearl: Order pre-op labs, psych eval, nutrition consult, and continue all visits — don't drop counseling once surgery is planned.
— Avoid hepatotoxic medications; acetaminophen still preferred over NSAIDs (renal) at standard weight-based dosing
— Vitamin E (800 IU/day) considered in biopsy-proven NASH without diabetes (pediatric data limited)
— No pharmacologic NAFLD-specific therapy is FDA-approved in children — weight loss is the only proven treatment
— GLP-1 agonists improve hepatic steatosis as a beneficial off-target effect
— Hypertension management: ACE inhibitor or ARB first-line if proteinuria; monitor K+, creatinine
— Avoid metformin if eGFR <30; reduce dose if 30–45
— Orlistat can cause oxalate nephropathy — avoid in CKD
— Aggressive BP control: target <90th percentile (or <130/80 in adolescents)
— Metformin first-line, titrate to 2 g/day
— Liraglutide (≥10) or exenatide ER (≥10) if A1c not at goal
— Insulin if A1c >8.5% at diagnosis or DKA presentation
— Newer agents (empagliflozin ≥10 years now approved for T2DM) — monitor for euglycemic DKA, GU infections
— Begin transition planning by age 14; transfer by 18–21
— Warm handoff to adult primary care + endocrine + bariatric follow-up
— Highest-risk window for loss to follow-up and weight regain
Step 3 management: A 17-year-old with BMI 42, T2DM, and NASH approaching transition needs a coordinated handoff: identify adult PCP, endocrinologist, hepatologist, send records, and schedule first adult visit before discharging from pediatric care.
Board pearl: Adolescent obesity care has the highest dropout rate at transition — Step 3 rewards proactive transition planning, not reactive triage.
— Increased risk of gestational diabetes, preeclampsia, cesarean delivery, macrosomia, neural tube defects, stillbirth
— Folic acid 0.4 mg daily preconception (or 4 mg if prior NTD-affected pregnancy or on antiepileptics)
— Preconception counseling: optimize weight, A1c <6.5% if diabetic, BP control
— Stop teratogenic obesity meds: topiramate, phentermine, orlistat (limited data); GLP-1 agonists held 2 months before conception
— Bariatric surgery: avoid pregnancy 12–18 months post-op; use non-oral contraception (IUD, implant) after RYGB due to malabsorption
— Diagnosis requires both oligo/amenorrhea ≥2 years post-menarche AND clinical or biochemical hyperandrogenism — ovarian morphology NOT used in adolescents
— Lifestyle first; combined OCPs for menstrual regulation and hyperandrogenism; metformin for metabolic features
— Screen for OSA, NAFLD, depression
— Use WHO weight-for-length, not BMI
— Avoid caloric restriction; focus on responsive feeding, eliminating sugar-sweetened beverages, no juice <1 year, limited juice (4 oz/day) age 1–3
— No screens <18 months except video chat; ≤1 hour/day age 2–5
— Higher obesity prevalence (Down syndrome, autism, cerebral palsy, spina bifida)
— Adapt exercise prescriptions; involve PT/OT
— Screen for medication-induced weight gain (antipsychotics)
— Higher prevalence in Hispanic, Black, Native American children
— Food deserts, structural racism, marketing of ultra-processed foods to children of color
— Use culturally relevant nutrition counseling; involve community resources (WIC, SNAP, school programs)
Key distinction: PCOS in adults uses Rotterdam criteria including ultrasound; adolescent PCOS does NOT use ovarian morphology because multifollicular ovaries are normal in puberty.
Board pearl: Always discontinue topiramate-containing obesity therapy before pregnancy attempts — high NTD and oral cleft risk.
— Type 2 diabetes — adolescent T2DM is more aggressive than adult-onset; faster beta-cell failure, earlier complications
— Prediabetes, metabolic syndrome
— PCOS in adolescent girls
— Premature adrenarche, early puberty (girls) / delayed puberty (some boys)
— Dyslipidemia, atherogenic lipid profile
— NAFLD — now the most common chronic liver disease in US children
— NASH → fibrosis → cirrhosis possible even in adolescence
— Pediatric liver transplant for NASH cirrhosis is increasing
— Hypertension, LVH on echo
— Endothelial dysfunction, accelerated atherosclerosis (fatty streaks present in adolescents)
— Higher lifetime CV mortality
— Obstructive sleep apnea (15–25% of obese children)
— Obesity hypoventilation syndrome (severe)
— Asthma worsening — obesity-related asthma is steroid-resistant
— Slipped capital femoral epiphysis (SCFE) — obese adolescents, presents with hip/knee pain, externally rotated leg, urgent surgical fixation
— Blount disease (tibia vara) — pathologic genu varum after age 3
— Flat feet, joint pain, fractures
— Idiopathic intracranial hypertension (pseudotumor cerebri) — headaches, vision changes, papilledema; risk of permanent vision loss
— Migraine, cognitive effects of OSA
— Depression (2–3× higher), anxiety, suicidal ideation
— Bullying, weight-based stigma, body dissatisfaction
— Eating disorders including binge-eating disorder (50% of adolescents with severe obesity) and ARFID
— Lower academic performance, social isolation
— Cholelithiasis, GERD, urinary incontinence, intertrigo, hidradenitis suppurativa
— Vitamin D deficiency
Board pearl: Hip or knee pain in an obese adolescent = SCFE until proven otherwise — non-weight-bearing immediately, urgent imaging, orthopedics. Missed SCFE causes avascular necrosis and lifelong disability.
Step 3 management: Always screen for eating disorders before initiating intensive weight loss — restrictive treatments can worsen binge eating and ARFID.
— Suspected SCFE: non-weight-bearing, urgent ortho consult and bilateral hip X-rays
— Pseudotumor cerebri with vision changes: ED → ophthalmology, neurology, LP
— DKA presentation of new T2DM: ED, ICU likely
— Acute suicidal ideation: ED psychiatric evaluation
— Severe OSA with hypoventilation, cor pulmonale signs: inpatient sleep medicine
— Pediatric endocrinology: suspected secondary obesity (short stature, dysmorphism, hyperphagia <5 yr); T2DM; severe insulin resistance; PCOS not responding to first-line; abnormal puberty
— Genetics: early-onset severe obesity + hyperphagia; syndromic features; family clustering of severe obesity
— Pediatric gastroenterology/hepatology: persistent ALT >2× ULN, suspected NASH, biopsy decision
— Sleep medicine: OSA symptoms, refer for polysomnography
— ENT: confirmed OSA with adenotonsillar hypertrophy for T&A
— Orthopedics: suspected SCFE, Blount disease, persistent musculoskeletal pain
— Psychology/psychiatry: depression, anxiety, eating disorder screening positive, family conflict around weight
— Registered dietitian (RDN): ideally embedded in primary care or accessible within IHBLT program
— Pediatric obesity medicine specialist: for pharmacotherapy consideration, severe obesity
— Bariatric surgery center (multidisciplinary): BMI thresholds met (see chunk 8)
— Pediatric obesity itself is not an admission indication, but complications are: DKA, hypertensive emergency, severe OSA needing titration, surgical complications, pseudotumor with vision loss
— Connect with WIC, SNAP, school nutrition programs, YMCA/community recreation, food banks
— Behavioral health integration in primary care improves outcomes
Step 3 management: Don't manage severe obesity (BMI ≥140% of 95th) alone in primary care — refer to a comprehensive pediatric weight management program at diagnosis.
Board pearl: The most commonly missed referral in primary care is bariatric surgery for eligible adolescents — clinician bias against pediatric MBS is well-documented but evidence-unsupported.
— >99% of cases; positive energy balance over time
— Normal/accelerated linear growth, normal development, family obesogenic environment
— Diagnosis of exclusion after ruling out red flags
— Weight gain modest (5–10 lb usually); short stature, growth deceleration, fatigue, constipation, bradycardia, delayed reflexes
— Screen with TSH, free T4
— Weight loss after treatment is modest — hypothyroidism alone rarely causes severe obesity
— Growth deceleration + weight gain is the cardinal feature
— Moon facies, buffalo hump, wide purple striae, hypertension, acne, hirsutism, proximal muscle weakness
— Screen: 24-hour urine free cortisol, late-night salivary cortisol, low-dose dex suppression
— Most common cause in children: exogenous glucocorticoids (asthma, IBD, transplant)
— Short stature, central adiposity, immature facial features, delayed bone age
— IGF-1, IGFBP-3, GH stim testing
— Hypoglycemia + weight gain
— Fasting insulin and glucose, C-peptide
— After craniopharyngioma resection, brain tumor, TBI, cranial radiation
— Hyperphagia, low metabolic rate, sleep disruption
— Difficult to treat; setmelanotide investigational; standard pharmacotherapy less effective
— Short stature, round facies, short 4th/5th metacarpals, obesity, intellectual disability
— Resistance to PTH (high PTH, low calcium, high phosphate)
Key distinction: The growth curve is the single best discriminator: exogenous obesity → tall or normal height; endocrine obesity → short or growth-decelerating. Always plot height alongside weight.
Board pearl: A child on chronic inhaled or systemic steroids who develops central obesity and growth failure has iatrogenic Cushing — review medication list before ordering expensive workups.
— Most common monogenic obesity (~2–5% of severe early-onset obesity)
— Hyperphagia from infancy, accelerated linear growth, tall stature, increased lean mass
— Autosomal dominant or codominant
— Setmelanotide trials ongoing
— Extreme hyperphagia, severe obesity from infancy, hypogonadotropic hypogonadism, immune dysfunction
— Low/undetectable leptin levels
— Recombinant leptin (metreleptin) is curative
— Similar phenotype to leptin deficiency but normal/high leptin
— POMC deficiency: red hair, adrenal insufficiency
— Setmelanotide FDA-approved
— Neonatal hypotonia and poor feeding, then hyperphagia age 2–6
— Short stature, small hands/feet, hypogonadism, intellectual disability, characteristic facies
— Loss of paternal 15q11-q13 expression; methylation testing
— GH therapy improves body composition
— Obesity, rod-cone dystrophy (night blindness), polydactyly, renal anomalies, hypogonadism, intellectual disability
— Setmelanotide approved
— Obesity, retinal dystrophy, sensorineural hearing loss, cardiomyopathy, T2DM
— Atypical antipsychotics (olanzapine, risperidone, quetiapine) — highest risk
— Systemic glucocorticoids
— Insulin, sulfonylureas
— Valproate, gabapentin, pregabalin
— Some antihistamines (cyproheptadine deliberately used for appetite)
— Tricyclic antidepressants, mirtazapine, paroxetine
— Beta-blockers (modest)
— Edema, ascites, large muscle mass (athletes) — high BMI without adiposity
— Use body composition assessment if uncertain (skinfolds, BIA, DEXA in research)
Board pearl: Any child on a second-generation antipsychotic requires baseline and quarterly BMI, glucose, lipid monitoring — failure to do so is a documented patient safety failure on Step 3.
Key distinction: Athletic teens with high BMI but normal blood pressure, normal labs, low waist-to-height ratio do not have obesity-related disease; BMI is a screen, not a diagnosis.
— Pediatric obesity is a lifelong, relapsing condition, not a behavior to be corrected
— Treatment is indefinite, like asthma or hypertension
— Counsel families against "diet cycles" and yo-yo expectations
— 5 servings fruits/vegetables daily
— 2 hours or less recreational screen time
— 1 hour or more physical activity daily
— 0 sugar-sweetened beverages
— Plus adequate sleep, family meals, no eating in front of screens
— Whole foods, minimally processed
— Adequate protein at each meal, fiber, healthy fats
— Water as primary beverage; milk per age guidelines
— Avoid labeling foods "good" vs "bad"; teach moderation
— No restrictive elimination diets in growing children without specialist oversight
— Combination of moderate-vigorous aerobic + muscle-strengthening 3 days/week + bone-loading activity
— Family-based, enjoyable, accessible
— Active transportation, after-school programs
— Anti-obesity medications continue indefinitely if effective and tolerated
— Reassess every 3–6 months; discontinue only if <4% BMI reduction at 12 weeks at full dose or intolerable side effects
— Post-bariatric: lifelong vitamin/mineral supplementation, A1c, lipids, ALT, bone density monitoring
— Treat HTN, T2DM, dyslipidemia, NAFLD, OSA on their own merits — don't defer "until weight is better"
— Statins per pediatric NHLBI guidelines: consider age ≥10 if LDL ≥190, or ≥160 with risk factors, or ≥130 with diabetes/family history
— Aspirin not routinely used in pediatric obesity
— Annual influenza (obesity is a high-risk indication)
— Routine schedule + COVID-19 boosters per CDC
Step 3 management: Treat comorbidities concurrently with weight management. Waiting for weight loss to "fix" diabetes or hypertension is malpractice — start ACE inhibitor, metformin, statin per pediatric thresholds now.
Board pearl: GLP-1 discontinuation = weight regain. Frame these medications as chronic, like an antihypertensive.
— IHBLT phase: ideally weekly to bi-weekly for ≥26 contact hours over 3–12 months; intensity matters more than total duration
— Maintenance phase: monthly for 6 months after intensive phase, then quarterly
— On pharmacotherapy: every 4 weeks during titration, then every 3 months
— Post-bariatric surgery: 2 weeks, 6 weeks, 3 months, 6 months, then yearly lifelong
— BMI, BP at every visit
— A1c, fasting glucose, lipids, ALT/AST every 6–12 months if previously abnormal; annually if normal and BMI ≥95th
— Vitamin D, B12, iron, calcium, PTH after bariatric surgery
— Microalbumin, dilated eye exam if T2DM
— Periodic mental health screening (PHQ-A annually ≥12 years)
— Self-reported diet (24-hour recall, food diary), activity logs, screen time, sleep hours
— Family meal frequency, who shops/cooks
— Mood, social functioning, school performance
— Motivation/readiness for change
— Barriers (cost, transportation, food access, time, parental health)
— Motivational interviewing: open-ended questions, affirmations, reflective listening, summarizing
— Avoid weight-focused language with children; use behavior-focused language
— Don't weigh in front of the child unless clinically necessary; consider blind weights
— Avoid lectures, scare tactics, parental shaming
— Involve the child age-appropriately in goal setting
— Parents/caregivers are the primary change agents in children <12
— Adolescents need increasing autonomy with parental support
— Sibling and household changes amplify effects
CCS pearl: In a virtual case, schedule follow-up at 2 weeks, then 1 month after starting any obesity intervention — gaps in follow-up are penalized and reflect real-world adherence drops.
Board pearl: Most counseling failure is dose failure — clinicians prescribe insufficient contact hours, not the wrong content.
— Provider weight bias is well-documented; affects diagnosis, treatment, and patient trust
— Use person-first language ("child with obesity," not "obese child")
— Avoid moralizing food, blaming parents, or shaming children
— Audit your own practice — biased communication drives loss to follow-up
— Bariatric surgery and anti-obesity medications require thorough informed consent: alternatives, expected outcomes, risks, lifelong implications
— Adolescents typically have assent, parents/guardians provide consent — but engage adolescent meaningfully
— Pregnancy counseling mandatory before topiramate/phentermine combo (teratogenicity) and GLP-1 (data limited; held preconception)
— Discuss off-label use when applicable (metformin for obesity, etc.)
— Provide private time with adolescent during visits
— Substance use, sexual activity, mood disclosed by adolescent generally confidential unless imminent harm
— Document carefully; state-specific rules vary
— Severe obesity itself is NOT child abuse in nearly all jurisdictions
— Medical neglect reporting threshold is very high: documented failure to address life-threatening comorbidity despite extensive support, not weight alone
— Removing children from families for obesity has caused harm and is broadly discouraged
— Report if there is withholding of insulin, refusal of evaluation for failure to thrive in younger sibling, etc.
— Aggressive weight loss messaging in vulnerable youth can precipitate anorexia, ARFID, bulimia, binge eating
— Screen before, during, after intervention (SCOFF, history of restriction/purging, body image)
— If eating disorder identified, pause weight loss intervention and refer to adolescent medicine/eating disorder specialist
— Anti-obesity pharmacotherapy and bariatric surgery are inequitably distributed — Step 3 may test on insurance, prior authorization, social determinants
— Advocate for coverage; document medical necessity
— Highest-risk window for medication errors, follow-up gaps; warm handoff to adult providers mandatory
Step 3 management: When a parent demands bariatric surgery for a 9-year-old with severe obesity, your role is to counsel respectfully, address comorbidities aggressively, and explain age-based criteria — not to dismiss or reprimand.
Board pearl: Always screen for eating disorders before initiating weight loss treatment; missing an underlying ED is a common Step 3 patient safety scenario.
Board pearl: The single most useful exam discriminator for secondary obesity remains the growth curve — short stature flips the differential.
Step 3 management: Plot height with weight at every visit, every time.
— 12-year-old presents for well-child exam. BMI 31 (>99th percentile). Acanthosis nigricans on neck. Snoring at night. Next best step?
— Answer: Fasting lipids, ALT/AST, fasting glucose AND A1c; refer for polysomnography; initiate IHBLT
— Trap: ordering TSH "just to screen" — not indicated without growth failure
— Child with weight gain, height velocity declining, fatigue, constipation
— Answer: TSH, free T4 → hypothyroidism workup
— Variant: weight gain + growth failure + striae + moon facies → Cushing workup (24-hr UFC)
— Obese 13-year-old with knee pain, externally rotated foot, antalgic gait
— Answer: Non-weight-bearing, bilateral hip X-ray, urgent ortho — knee pain is referred from hip
— Trap: ordering knee X-ray first — misses SCFE
— Obese adolescent girl with headaches and blurred vision, papilledema on fundoscopy
— Answer: MRI/MRV brain, then LP with opening pressure, ophthalmology consult, acetazolamide, weight loss
— Trap: starting migraine therapy without fundoscopy
— 14-year-old with BMI 36, A1c 6.0%, completed 6 months of intensive lifestyle program with minimal change
— Answer: Add semaglutide or liraglutide while continuing lifestyle
— Trap: repeating another 6 months of lifestyle alone
— 15-year-old with BMI 42, T2DM on metformin + insulin, OSA, NASH on biopsy
— Answer: Refer to comprehensive pediatric bariatric surgery program
— Trap: deeming "too young" — current guidelines support ≥13 years with criteria
— Severe obesity onset age 1, hyperphagic, weight 60 kg at age 5, red hair, low cortisol
— Answer: POMC deficiency — setmelanotide after genetic confirmation
— 8-year-old on risperidone for autism with rapid weight gain
— Answer: Review monitoring labs (baseline + quarterly missed?), consider switch to lower-weight-gain agent (aripiprazole), counsel family
— 16-year-old with severe obesity on weight loss program, recent rapid loss, secretive eating, vomiting
— Answer: Pause aggressive weight loss, screen for bulimia/binge-eating, refer adolescent medicine
Board pearl: When a Step 3 stem includes a growth curve, look at it first — it often tells the diagnosis before the labs.
Pediatric obesity is a chronic, treatable disease requiring early identification by BMI plotting, comorbidity screening calibrated to severity, intensive family-based behavioral treatment as the foundation, and timely escalation to pharmacotherapy and bariatric surgery in eligible adolescents — without weight stigma and with rigorous attention to growth curve red flags signaling secondary causes.
Board pearl: If you remember nothing else: plot the curve, calculate % of 95th, treat early and intensively, escalate without delay, and never stigmatize the patient.